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ABSTRACT
B-cell targeted therapies (BCTT) are now widely used 
in autoimmune rheumatic diseases, including SLE, 
antineutrophil cytoplasmic antibody-associated vasculitis 
and rheumatoid arthritis. Early studies suggested that 
rituximab did not influence serum immunoglobulins. 
However, subsequently, with increased patient numbers, 
longer follow-up duration and many patients having 
received multiple BCTT courses, multiple subsequent 
studies have identified hypogammaglobulinaemia 
as a potential side effect. Patients developing 
hypogammaglobulinaemia appear to fit into two principal 
categories: the majority who develop transient, often 
mild reduction in immunoglobulins without increased 
infection and a much smaller but clinically significant group 
with a more sustained antibody deficiency, who display 
increased risk of infection. Monitoring immunoglobulin 
levels represents an opportunity for the early detection of 
hypogammaglobulinaemia, and the prevention of avoidable 
morbidity. In the two major studies, approximately 4%–5% 
of BCTT-treated patients required immunoglobulin 
replacement due to recurrent infections in the context of 
hypogammaglobulinaemia. Despite this, monitoring of 
immunoglobulins is suboptimal, and there remains a lack 
of awareness of hypogammaglobulinaemia as an important 
side effect.
Over the last 15 years, B-cell targeted thera-
pies (BCTT) have been widely used for treat-
ment of autoimmune rheumatic diseases 
(AIRD), particularly in severe/resistant cases 
of SLE, and in antineutrophil cytoplasmic 
antibody-associated vasculitis (AAV). These 
medications are also employed in rheumatoid 
arthritis (RA) and multiple sclerosis.1
Initial studies suggested that rituximab, the 
earliest and still most widely reported BCTT, 
did not influence serum immunoglobulins. 
This was based on early studies of limited doses 
and duration, and the premise that plasma 
cells did not express surface CD20, the molec-
ular target of rituximab. It was also proposed 
that protective antimicrobial antibodies were 
not significantly affected, in contrast to reduc-
tion in pathogenic autoantibodies; based 
on findings that B-cell clones producing 
antinucleosome and antidouble-stranded 
DNA antibodies, had a relatively rapid turn-
over compared with B-cell clones with other 
specificities.2
Over time, large numbers of patients have 
been treated, with longer follow-up duration, 
and many patients have received multiple 
BCTT courses. In this context, multiple subse-
quent studies have now identified hypogam-
maglobulinaemia as a potential side effect. 
The patients developing hypogammaglob-
ulinaemia appear to fall into two main cate-
gories: the majority who develop transient, 
often mild reduction in immunoglobulins 
without increased infection and a much 
smaller but clinically significant group with 
a more sustained antibody deficiency, who 
display increased risk of infection.3 This may 
result from prolonged depletion of plasma 
cell precursors, with consequent effects on 
replenishment of mature plasma cells.
Monitoring immunoglobulin levels 
represents an opportunity for the early detec-
tion of hypogammaglobulinaemia, and can 
be performed using cheap, simple and widely 
available assays. The American Academy 
of Allergy, Asthma & Immunology, British 
Society for Rheumatology (BSR) and Euro-
pean League against Rheumatism (EULAR) 
advocate testing immunoglobulins at base-
line, and BSR and EULAR at varying times 
after commencement of BCTT in AAV and 
RA. Although the 2018 BSR SLE guidelines 
advocate baseline and follow-up testing of 
immunoglobulins patients treated with ritux-
imab (also with other drugs such as mycophe-
nolate and cyclophosphamide), monitoring 
is not mentioned in the 2019 EULAR SLE 
recommendations.4 5
There still appears to be little awareness of 
this important side effect, with a lack of wide-
spread adoption of immunoglobulin moni-
toring in patients treated with BCTT. This 
represents a lost opportunity in early preven-
tion of avoidable morbidity. In a large Boston 
study, 3824/4479 (85%) of rituximab-treated 
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patients (including AIRD and haematological disor-
ders) had never had immunoglobulins checked prior to 
BCTT commencement.3 Of those who were checked at 
baseline, hypogammaglobulinaemia was present in 313 
(47.8%) patients. The BSR Biologics Registry includes 
over 5000 patients who have received rituximab. Several 
BSR Biologics Registry publications emerged in late 
2018, assessing the risk of infection in rituximab-treated 
patients. However, the Registry did not collect data on 
measurement of immunoglobulins, and this critical 
parameter was therefore not evaluated as a risk factor for 
serious infection.6
Although most patients with hypogammaglobulinaemia 
do not have problems with infections, hypogammaglobu-
linaemia has been shown to be a risk factor for infections 
in several BCTT studies. In AAV, logistic regression anal-
ysis after adjustment for age, race and estimated glomer-
ular filtration rate showed increased risk of hospitalisation 
from infection (OR 21.1; 95% CI 1.1 to 404.1; p = 0.04) 
for patients with IgG <3.75 g/L.7 In RA, patients with 
hypogammaglobulinaemia (<6 g/L) were more likely to 
experience severe infections (26.1% vs 6.3%, p=0.033).8
Infections characteristic of hypogammaglobulinaemia 
are usually sino-pulmonary, caused by encapsulated organ-
isms such as pneumococci. The diagnostic delay common 
in primary antibody deficiency is now known also to 
occur in secondary antibody deficiency, and may extend 
to several years. This often avoidable delay can result in 
unnecessary admissions and complications such as bron-
chiectasis.9 10 In some cases, patients with hypogamma-
globulinaemia can present for the first time with sepsis, 
for example, related to pneumococci or meningococci, 
without an antecedent history of recurrent infection. In 
addition, enteroviral encephalitis has been described in 
rituximab-induced hypogammaglobulinaemia.11
Hypogammaglobulinaemia at initiation of anti-CD20 
treatment may be transient, and multifactorial, including 
effects of other medications (eg, corticosteroids, cyclo-
phosphamide, mycophenolate mofetil), or active disease 
(eg, nephrotic syndrome). However, hypogammaglobuli-
naemia occurring later after BCTT may be sustained, and 
related to prolonged B-cell depletion. Predictive factors 
for such hypogammaglobulinaemia include low baseline 
immunoglobulins (especially IgG) at BCTT commence-
ment, and possibly previous or concomitant immunosup-
pressive therapies (such as cyclophosphamide).12 The 
frequency of hypogammaglobulinaemia appears higher 
in certain AIRD, for example, AAV, SLE compared with 
RA, although the exact reasons are not yet known.
Immunological disorders were previously categorised 
into those due to allergy, autoimmunity or immunode-
ficiency. However, there is now recognition that more 
than one type of immunopathology may co-exist in the 
same patient, with the common underlying pathology 
being immunodysregulation. Hence, common variable 
immunodeficiency (the most frequent cause of primary 
antibody deficiency) may display several different auto-
immune phenomena, including cytopenia, inflammatory 
arthritis and SLE.13 Baseline measurement of immuno-
globulins is thus also important to help exclude a more 
complex immunological phenotype.3
With this increased risk of infection, it is critical that 
the recommended monitoring schedules are incorpo-
rated into routine clinical protocols for currently avail-
able BCTT. It is important that clinicians are aware of 
hypogammaglobulinaemia as a potential side effect, and 
counsel their patients appropriately prior to commence-
ment of treatment. Clinicians treating AIRD should be 
cognizant of local clinical immunology services and 
referral pathways. In patients with hypogammaglobuli-
naemia with recurrent or serious infections, consideration 
can be made for referral to clinical immunology to eval-
uate for immunoglobulin replacement therapy (IGRT). 
It is important to bear in mind that IGRT is an expen-
sive treatment, a major commitment by both patients 
and clinical staff of medium-term or long-term (poten-
tially lifelong) duration, with attendant risks including 
thrombosis and infusion-related infections from known 
and unknown agents. Thankfully, with improved donor 
screening, and three-step antiviral processes, there have 
been no recent cases of hepatitis C, HIV or prion disease 
acquired through IGRT.14 IGRT should be reviewed at 
regular intervals, primarily to ensure that the therapy 
is effective and side effects minimised, and there is the 
chance that endogenous antibody production may return 
in the long-term.
Our group has recently published recommendations 
for management of secondary hypogammaglobulinaemia 
due to BCTT in AIRD.1 Clinical evaluation should take 
into account the degree of hypogammaglobulinaemia, 
infection history, assessment of antibody responses to 
polysaccharide antigens and whether a trial of antibiotic 
prophylaxis is appropriate. Measurement of antibody 
responses 4–8 weeks after administration of the non-con-
jugated pneumococcal polysaccharide vaccine is typically 
used in the assessment of hypogammaglobulinaemia to 
identify functional/specific antibody deficiency.1 15–17 The 
UK16 guidelines recommend initiating IGRT in patients 
with secondary hypogammaglobulinaemia of any cause 
(IgG <5 g/L), functional antibody deficiency and failure 
of antibiotic prophylaxis over 3 months in preventing 
infections.16 These guidelines are currently in the process 
of revision. Although there is no supportive evidence avail-
able, we would suggest that in some settings, for example, 
a history of severe/life-threatening infections with very 
low IgG levels (<1–2 g/L) together with absent/very 
impaired (postvaccination) specific antibody responses, 
it may be appropriate to consider IGRT without a trial 
of antibiotic prophylaxis. In 2018, the European Medi-
cines Agency Guideline for Human Normal Immuno-
globulin for Intravenous Administration advised IGRT 
in secondary immunodeficiency with severe or recurrent 
infections, ineffective antimicrobial treatment and either 
serum IgG level of <4 g/L or proven specific antibody 
failure.15 An IgG value of 4 g/L is also noted as a level 
for consideration of IGRT in other reviews of secondary 
Wijetilleka S, et al. Lupus Science & Medicine 2019;6:e000337. doi:10.1136/lupus-2019-000337 3
Brief communication
Box 1. Practical guidance for management of 
hypogammaglobulinaemia in B-cell targeted therapies 
(BCTT)-treated patients
 ► Assess infection history.
 ► Check specific antimicrobial antibodies±vaccine responses.
 ► If no infections, continue to monitor immunoglobulins pre-infusion 
and/or at regular intervals.
 ► Consider referral to clinical immunology if IgG <4 g/L and/or signif-
icant infection history.
 ► Consider if there is potential alternative immunosuppression to 
BCTT.
 ► Consider prophylactic antibiotic therapy.
 ► Immunoglobulin replacement therapy in selected cases.
antibody deficiency.17 18 In hypogammaglobulinaemia 
related to chronic lymphocytic leukaemia, the majority of 
infections occurred when IgG was below 3 g/L.19 Cana-
dian guidelines from 2018 refer to IgG below the lower 
limit of the reference range on two occasions.20
The literature suggests only a minority of patients devel-
oping BCTT-induced hypogammaglobulinaemia will 
require IGRT. In the two largest series of IGRT in BCTT-
treated patients, the rates of immunoglobulin use are 
remarkably similar. In the Cambridge (UK) study, 12/288 
(4.2%) patients with AIRD treated with BCTT went on to 
receive IGRT, while in the Boston study 201/4479 (4.5%) 
received IGRT, although this study also included patients 
without AIRD.3 21 There is early evidence for the efficacy 
of IGRT in reducing infection in BCTT-related hypogam-
maglobulinaemia, as well as substantial evidence from 
other secondary antibody deficiencies.9 17 22 In the Boston 
study,3 higher cumulative IGRT dose was associated with 
a reduced risk of serious infectious complications (HR 
0.98; 95% CI 0.96 to 0.99; p=0.002).
The importance of vaccination in relation to biologic 
therapy in SLE and other AIRD is highlighted in multiple 
guidelines, both from rheumatology and microbiology 
perspectives.5 23 The importance of early vaccination is 
emphasised for appropriate organisms (such as influ-
enza, Streptococcus pneumoniae, Haemophilus influenzae) 
in patients with AIRD, as there is reduction in antibody 
responses to vaccinations for 1–6 months following anti-
CD20 treatment. If vaccination cannot be administered 
early, then it may be prudent to wait until beyond this 
period. As mentioned in the 2018 BSR SLE guidelines, 
postvaccination antibody levels can be measured to assess 
response.4
Based on recent guidelines and recommendations, we 
have summarised a possible approach to management of 
hypogammaglobulinaemia in patients treated with BCTT 
(Box 1).
Over time, further experience will emerge for different 
BCTT, and different BCTT regimens, and predictive 
factors for hypogammaglobulinaemia may be identified. 
There is insufficient data from other B-cell depletors ocre-
lizumab and epratuzumab in autoimmune disease, and 
no data demonstrating clinically significant hypogamma-
globulinaemia in SLE with non-depleting BCTT such as 
atacicept or belimumab.12 However, it would be prudent 
to avoid definite conclusions at this stage given the inad-
vertent reassurance regarding potential effects of ritux-
imab on humoral immunity based on early data.
Consequently, it is important to re-evaluate all BCTT 
with larger numbers of patients treated, long-term 
follow-up and also the effects of repeat dosing and multiple 
drug interventions. Although use of conventional immu-
nosuppressive agents is reducing, corticosteroids, cyclo-
phosphamide, mycophenolate can all influence B-cell 
function and prior use may influence the development 
of hypogammaglobulinaemia following biologic use.8 12 
Combinations of biologics affecting B-cells are used in 
clinical trials, for example, rituximab and belimumab 
in the BEATLupus, BLISS-BELIEVE and CALIBRATE 
studies. It is too early to evaluate the data assessing the 
long-term effects on protective humoral immunity from 
such combinations.
Monitoring of immunoglobulins is important to 
consider with biosimilars and with newer BCTT, both in 
current clinical trials and for future agents. This moni-
toring should be considered both as an essential compo-
nent of trial data, and as part of routine clinical care. This 
should include all B-cell active agents, to include B-cell 
monoclonal antibodies, other BCTT such as btk-inhibitors 
as well as plasma cell agents (eg, anti-CD38, proteasome 
inhibitors).
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